Protara Therapeutics (TARA) CEO exercises options, sells 215,687 shares and makes 30,000-share gifts

Rhea-AI Filing Summary

Protara Therapeutics, Inc. CEO Jesse Shefferman reported multiple equity transactions in Protara common stock. On June 29, 2026, he exercised stock options to acquire 215,687 shares at an exercise price of $1.91 per share and sold 215,687 shares in open-market transactions at a weighted average price of $4.09 per share, with individual sale prices ranging from $4.03 to $4.14.

On June 30, 2026, Shefferman made bona fide gift transfers totaling 30,000 shares of common stock in four separate transactions. Following these transactions, he holds 691,832 shares directly and 300,000 shares indirectly through The Samhold Family Trust, and 141,313 stock options with a $1.91 exercise price expiring on January 18, 2034.

Insights

Equity compensation analyst

CEO executes option exercise-and-sell plus share gifts, retaining a sizable equity stake.

CEO Jesse Shefferman exercised options for 215,687 shares at an exercise price of $1.91 and sold the same number of shares at a weighted average of $4.09, with trades between $4.03 and $4.14. This pattern reflects a typical exercise-and-sell event converting options into cash.

He also made bona fide gifts totaling 30,000 shares the next day, which are non-economic transfers rather than market sales. After these moves, he still directly owns 691,832 shares and indirectly holds 300,000 shares via The Samhold Family Trust, plus 141,313 remaining options expiring on January 18, 2034. The filing also notes a standard disclaimer that he disclaims beneficial ownership beyond his pecuniary interest, underscoring technical reporting treatment rather than signaling a strategic shift.

Insider Trade Summary

Net Seller: 215,687 shares ($882,160)

Net Sell 8 txns

Insider Shefferman Jesse

Role CEO and President

Sold 215,687 shs ($882K)

Type	Security	Shares	Price	Value
Gift	Common Stock	14,000	$0.00	--
Gift	Common Stock	7,000	$0.00	--
Gift	Common Stock	4,000	$0.00	--
Gift	Common Stock	5,000	$0.00	--
Exercise	Stock Option (Right to Buy)	215,687	$0.00	--
Exercise	Common Stock	215,687	$1.91	$412K
Sale	Common Stock	215,687	$4.09	$882K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 707,832 shares (Direct, null); Stock Option (Right to Buy) — 141,313 shares (Direct, null); Common Stock — 300,000 shares (Indirect, The Samhold Family Trust)

Footnotes (1)

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.03 to $4.14, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest, and this report should not be deemed an admission that the Reporting Person or any other person named herein is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. The reported securities held by the Samhold Family Trust were inadvertently included under the Reporting Person's direct holdings in the prior Form 4 filings filed by the Reporting Person on January 21, 2026, January 22, 2026 and January 27, 2026. 25% of the shares underlying the option vested on January 19, 2025 and the remaining shares have vested or will vest in equal monthly installments thereafter over the following 36 months, subject to the Reporting Person's continuous service with the Issuer as of each such date.

Key Figures

Shares sold: 215,687 shares Sale price range: $4.03–$4.14 per share Options exercised: 215,687 shares at $1.91 +4 more

7 metrics

Shares sold 215,687 shares Open-market sale at weighted avg $4.09 on June 29, 2026

Sale price range $4.03–$4.14 per share Price range for 215,687 shares sold on June 29, 2026

Options exercised 215,687 shares at $1.91 Stock option exercise into common stock on June 29, 2026

Gifts of common stock 30,000 shares Four bona fide gifts on June 30, 2026 at $0.00

Direct holdings after transactions 691,832 shares Common stock directly owned after June 30, 2026 gifts

Indirect holdings via trust 300,000 shares Common stock held through The Samhold Family Trust

Remaining stock options 141,313 options at $1.91 Stock options expiring January 18, 2034

Key Terms

bona fide gift, weighted average price, Stock Option (Right to Buy), pecuniary interest, +1 more

5 terms

bona fide gift financial

"The transaction_code_description for multiple entries is "Bona fide gift"."

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"The derivative security title is "Stock Option (Right to Buy)"."

pecuniary interest financial

"The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest."

The Samhold Family Trust financial

"The reported securities held by The Samhold Family Trust were inadvertently included under direct holdings."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:11 PM Accepted by SEC EDGAR 07/01/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shefferman Jesse

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2026		M		215,687	A	$1.91	937,519	D
Common Stock	06/29/2026		S		215,687	D	$4.09(1)	721,832	D
Common Stock	06/30/2026		G		14,000	D	$0	707,832	D
Common Stock	06/30/2026		G		7,000	D	$0	700,832	D
Common Stock	06/30/2026		G		4,000	D	$0	696,832	D
Common Stock	06/30/2026		G		5,000	D	$0	691,832	D
Common Stock								300,000	I	The Samhold Family Trust(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.91	06/29/2026		M			215,687	(4)	01/18/2034	Common Stock	215,687	$0	141,313	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.03 to $4.14, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

2. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest, and this report should not be deemed an admission that the Reporting Person or any other person named herein is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

3. The reported securities held by the Samhold Family Trust were inadvertently included under the Reporting Person's direct holdings in the prior Form 4 filings filed by the Reporting Person on January 21, 2026, January 22, 2026 and January 27, 2026.

4. 25% of the shares underlying the option vested on January 19, 2025 and the remaining shares have vested or will vest in equal monthly installments thereafter over the following 36 months, subject to the Reporting Person's continuous service with the Issuer as of each such date.

Remarks:

	/s/ Jesse Shefferman	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did TARA CEO Jesse Shefferman do in this Form 4 filing?

TARA CEO Jesse Shefferman exercised stock options for 215,687 shares at $1.91 and sold 215,687 shares at a weighted average of $4.09. He also made bona fide gifts totaling 30,000 shares of Protara Therapeutics common stock.

How many Protara Therapeutics (TARA) shares did the CEO sell and at what price?

Shefferman sold 215,687 Protara Therapeutics common shares at a weighted average price of $4.09 per share. The sales occurred in multiple trades, with individual prices ranging from $4.03 to $4.14 on June 29, 2026.

How many TARA shares did the CEO receive through option exercises?

He exercised stock options covering 215,687 Protara Therapeutics common shares at an exercise price of $1.91 per share. After this exercise, 141,313 options with the same exercise price remained outstanding and are scheduled to expire on January 18, 2034.

What gifts of Protara Therapeutics (TARA) shares did the CEO make?

On June 30, 2026, Shefferman made four bona fide gift transfers totaling 30,000 Protara Therapeutics common shares. These gifts were reported at a price of $0.00 per share, reflecting non-economic transfers rather than open-market sales or purchases.

What are the CEO’s Protara Therapeutics share holdings after these transactions?

Following the reported transactions, Shefferman holds 691,832 Protara Therapeutics common shares directly and 300,000 shares indirectly through The Samhold Family Trust. He also has 141,313 outstanding stock options with a $1.91 exercise price expiring on January 18, 2034.

Does the TARA CEO claim full beneficial ownership of all reported shares?

The filing states that Shefferman disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest. This legal language clarifies how ownership is treated for Section 16 reporting and does not by itself indicate a change in economic exposure.